Home | Find A Doctor | Contact Us

 

A Phase II Prospective Trial Correlating Progression Free Survival with CYP2D6 Activity in Patients with Metastatic Breast Cancer Treated with Single Agent Tamoxifen


Principal Investigator: Paula Klein, MD
Time frame of study: Ongoing
Location of Study:

Mount Sinai Beth Israel
St.Luke's-Mount Sinai Roosevelt

Contact:

Continuum Cancer Research Program
(212) 844-6286

 

Summary:
Tamoxifen remains the most common endocrine intervention prescribed to women with all stages of hormone receptor positive breast cancer or to decrease the incidence of the disease. The overall goal of this clinical trial is to determine whether variants in CYP2D (gene) influence progression free survival and other outcomes in women with metastatic breast cancer, and to explore the role of other genetic variants.


Eligibility and Treatment Plan:
Age 18 or older
Estrogen and/or progesterone receptor positive adenocarcinoma of the breast
Stage III/locally advanced or metastatic carcinoma of the breast where surgery is not possible


Please call for more information.

 

 

Privacy Policy | Site Map
Copyright ©  Icahn School of Medicine at Mount Sinai | Mount Sinai Health System